The Europe Bronchodilators Market would witness market growth of 4.4% CAGR during the forecast period (2022-2028).
Corticosteroids commonly inhaled are added to beta-2 agonists to decrease pro-inflammatory agents and inflammation that further constrict airways. Beta-2 agonist class bronchodilators do not affect the underlying pathology of lung disease; they are only symptomatic treatments. Hence, adding inhaled corticosteroids to the regimen has been the mainstay of mild to moderate reversible lung diseases with or without long-acting beta-2 agonists. Anticholinergics are the final class of medicine that are considered bronchodilators.
This class's mechanism inhibits the effects of the parasympathetic nervous system medicated by the vagus nerve. A hyperactive parasympathetic nervous system causes airways and bronchial secretions to narrow. Medicines that inhibit the actions of the parasympathetic nervous system at the airway's low level will create a bronchodilatory effect.
These medicines include tiotropium bromide, which has a more prolonged effect of up to 24 hours, and ipratropium bromide, a short-acting medication that works for around 4 to 6 hours. Anticholinergics' primary function in the setting of chronic obstructive pulmonary disease. Patients with asthma can generally control their symptoms with a corticosteroid and a beta-2 agonist.
In England, smoking is one of the primary causes of health inequalities, with the harm focused on disadvantaged groups and communities. In 2019, around 13.9% of adults in England still smoked, approximately 6 million people. Smoking is one of the leading preventable causes of illness and premature death, responsible for around 74,600 deaths in England. In addition, one in 4 patients in a hospital bed is a smoker. The rising number of tobacco consumers will also increase the number of lung-based diseases and thereby surge the usage of medication like bronchodilators for their treatments, boosting the market growth in the region.
The Germany market dominated the Europe Bronchodilators Market by Country in 2021; thereby, achieving a market value of $1,671.7 million by 2028. The UK market is exhibiting a CAGR of 3.5% during (2022 - 2028). Additionally, The France market would experience a CAGR of 5.2% during (2022 - 2028).
Based on Drug Class, the market is segmented into Beta-Adrenergic, Xanthine Derivatives, and Anticholinergic. Based on Route of Administration, the market is segmented into Nasal (Inhalable), Oral, and Injectable. Based on Disease, the market is segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glenmark Pharmaceuticals Limited, Merck & Co., Inc., GlaxoSmithKline PLC, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Cipla Limited, Viatris, Inc., Novartis AG, Boehringer Ingelheim International GmbH and Sun Pharmaceutical Industries Ltd.
Corticosteroids commonly inhaled are added to beta-2 agonists to decrease pro-inflammatory agents and inflammation that further constrict airways. Beta-2 agonist class bronchodilators do not affect the underlying pathology of lung disease; they are only symptomatic treatments. Hence, adding inhaled corticosteroids to the regimen has been the mainstay of mild to moderate reversible lung diseases with or without long-acting beta-2 agonists. Anticholinergics are the final class of medicine that are considered bronchodilators.
This class's mechanism inhibits the effects of the parasympathetic nervous system medicated by the vagus nerve. A hyperactive parasympathetic nervous system causes airways and bronchial secretions to narrow. Medicines that inhibit the actions of the parasympathetic nervous system at the airway's low level will create a bronchodilatory effect.
These medicines include tiotropium bromide, which has a more prolonged effect of up to 24 hours, and ipratropium bromide, a short-acting medication that works for around 4 to 6 hours. Anticholinergics' primary function in the setting of chronic obstructive pulmonary disease. Patients with asthma can generally control their symptoms with a corticosteroid and a beta-2 agonist.
In England, smoking is one of the primary causes of health inequalities, with the harm focused on disadvantaged groups and communities. In 2019, around 13.9% of adults in England still smoked, approximately 6 million people. Smoking is one of the leading preventable causes of illness and premature death, responsible for around 74,600 deaths in England. In addition, one in 4 patients in a hospital bed is a smoker. The rising number of tobacco consumers will also increase the number of lung-based diseases and thereby surge the usage of medication like bronchodilators for their treatments, boosting the market growth in the region.
The Germany market dominated the Europe Bronchodilators Market by Country in 2021; thereby, achieving a market value of $1,671.7 million by 2028. The UK market is exhibiting a CAGR of 3.5% during (2022 - 2028). Additionally, The France market would experience a CAGR of 5.2% during (2022 - 2028).
Based on Drug Class, the market is segmented into Beta-Adrenergic, Xanthine Derivatives, and Anticholinergic. Based on Route of Administration, the market is segmented into Nasal (Inhalable), Oral, and Injectable. Based on Disease, the market is segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glenmark Pharmaceuticals Limited, Merck & Co., Inc., GlaxoSmithKline PLC, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Cipla Limited, Viatris, Inc., Novartis AG, Boehringer Ingelheim International GmbH and Sun Pharmaceutical Industries Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Drug Class
- Beta-Adrenergic
- Xanthine Derivatives
- Anticholinergic
By Route of Administration
- Nasal (Inhalable)
- Oral
- Injectable
By Disease
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Glenmark Pharmaceuticals Limited
- Merck & Co., Inc
- GlaxoSmithKline PLC
- AstraZeneca PLC
- Teva Pharmaceuticals Industries Ltd
- Cipla Limited
- Viatris, Inc
- Novartis AG
- Boehringer Ingelheim International GmbH
- Sun Pharmaceutical Industries Ltd
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Bronchodilators Market, by Drug Class
1.4.2 Europe Bronchodilators Market, by Route of Administration
1.4.3 Europe Bronchodilators Market, by Disease
1.4.4 Europe Bronchodilators Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Bronchodilators Market by Drug Class
3.1 Europe Beta-Adrenergic Market by Country
3.2 Europe Xanthine Derivatives Market by Country
3.3 Europe Anticholinergic Market by Country
Chapter 4. Europe Bronchodilators Market by Route of Administration
4.1 Europe Nasal (Inhalable) Market by Country
4.2 Europe Oral Market by Country
4.3 Europe Injectable Market by Country
Chapter 5. Europe Bronchodilators Market by Disease
5.1 Europe Asthma Market by Country
5.2 Europe Chronic Obstructive Pulmonary Disease (COPD) Market by Country
5.3 Europe Others Market by Country
Chapter 6. Europe Bronchodilators Market by Country
6.1 Germany Bronchodilators Market
6.1.1 Germany Bronchodilators Market by Drug Class
6.1.2 Germany Bronchodilators Market by Route of Administration
6.1.3 Germany Bronchodilators Market by Disease
6.2 UK Bronchodilators Market
6.2.1 UK Bronchodilators Market by Drug Class
6.2.2 UK Bronchodilators Market by Route of Administration
6.2.3 UK Bronchodilators Market by Disease
6.3 France Bronchodilators Market
6.3.1 France Bronchodilators Market by Drug Class
6.3.2 France Bronchodilators Market by Route of Administration
6.3.3 France Bronchodilators Market by Disease
6.4 Russia Bronchodilators Market
6.4.1 Russia Bronchodilators Market by Drug Class
6.4.2 Russia Bronchodilators Market by Route of Administration
6.4.3 Russia Bronchodilators Market by Disease
6.5 Spain Bronchodilators Market
6.5.1 Spain Bronchodilators Market by Drug Class
6.5.2 Spain Bronchodilators Market by Route of Administration
6.5.3 Spain Bronchodilators Market by Disease
6.6 Italy Bronchodilators Market
6.6.1 Italy Bronchodilators Market by Drug Class
6.6.2 Italy Bronchodilators Market by Route of Administration
6.6.3 Italy Bronchodilators Market by Disease
6.7 Rest of Europe Bronchodilators Market
6.7.1 Rest of Europe Bronchodilators Market by Drug Class
6.7.2 Rest of Europe Bronchodilators Market by Route of Administration
6.7.3 Rest of Europe Bronchodilators Market by Disease
Chapter 7. Company Profiles
7.1 Glenmark Pharmaceuticals Limited
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Research & Development Expenses
7.1.4 Recent strategies and developments:
7.1.4.1 Product Launches and Product Expansions:
7.2 Merck & Co., Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expenses
7.3 GlaxoSmithKline PLC
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.4 AstraZeneca PLC
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.5 Teva Pharmaceutical Industries Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.6 Cipla Limited
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.7 Viatris, Inc. (Mylan N.V.)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 Novartis AG
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Boehringer Ingelheim International Gmbh
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional & Segmental Analysis
7.9.4 Research & Development Expenses
7.10. Sun Pharmaceutical Industries Ltd.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional & Segmental Analysis
7.10.4 Research & Development Expenses
Companies Mentioned
- Glenmark Pharmaceuticals Limited
- Merck & Co., Inc.
- GlaxoSmithKline PLC
- AstraZeneca PLC
- Teva Pharmaceuticals Industries Ltd.
- Cipla Limited
- Viatris, Inc.
- Novartis AG
- Boehringer Ingelheim International GmbH
- Sun Pharmaceutical Industries Ltd.
Methodology
LOADING...
